Gerresheimer AG (ETR:GXI) has been given a €80.00 ($91.95) price objective by analysts at Hauck & Aufhaeuser in a research note issued to investors on Friday. The firm presently has a “neutral” rating on the stock.
Other equities analysts also recently issued reports about the company. Kepler Capital Markets set a €70.00 ($80.46) price target on Gerresheimer AG and gave the stock a “sell” rating in a research note on Thursday, July 13th. Commerzbank Ag set a €73.00 ($83.91) target price on Gerresheimer AG and gave the company a “neutral” rating in a research report on Monday, June 26th. DZ Bank AG reiterated a “neutral” rating on shares of Gerresheimer AG in a research report on Friday, June 9th. Berenberg Bank set a €83.00 ($95.40) target price on Gerresheimer AG and gave the company a “buy” rating in a research report on Thursday, July 13th. Finally, Deutsche Bank AG set a €82.00 ($94.25) target price on Gerresheimer AG and gave the company a “buy” rating in a research report on Friday, July 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. Gerresheimer AG has a consensus rating of “Hold” and an average price target of €80.06 ($92.02).
Gerresheimer AG (ETR GXI) opened at 71.471 on Friday. The company’s 50 day moving average price is €74.42 and its 200 day moving average price is €73.18. Gerresheimer AG has a 12 month low of €64.00 and a 12 month high of €79.47. The stock has a market cap of €2.24 billion and a PE ratio of 19.028.
Gerresheimer AG Company Profile
Gerresheimer AG is a Germany-based company that is active in the pharmaceuticals and health care industry. It operates through two business segments: Plastics and Devices, and Primary Packaging Glass. The Plastics and Devices segment produces standard and customized products for drug delivery, such as insulin pens, inhalers, and prefillable syrings.
Receive News & Ratings for Gerresheimer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer AG and related companies with MarketBeat.com's FREE daily email newsletter.